- Home
- MMSI vs PRCT Comparison
MMSI vs PRCT Comparison
Compare MMSI & PRCT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MMSI
- PRCT
- Stock Information
- Founded
- MMSI 1987
- PRCT 2009
- Country
- MMSI United States
- PRCT United States
- Employees
- MMSI N/A
- PRCT N/A
- Industry
- MMSI Medical/Dental Instruments
- PRCT Medical Specialities
- Sector
- MMSI Health Care
- PRCT Health Care
- Exchange
- MMSI Nasdaq
- PRCT Nasdaq
- Market Cap
- MMSI 5.6B
- PRCT 4.7B
- IPO Year
- MMSI 1990
- PRCT 2021
- Fundamental
- Price
- MMSI $104.40
- PRCT $69.75
- Analyst Decision
- MMSI Strong Buy
- PRCT Strong Buy
- Analyst Count
- MMSI 10
- PRCT 7
- Target Price
- MMSI $108.10
- PRCT $97.86
- AVG Volume (30 Days)
- MMSI 508.3K
- PRCT 656.5K
- Earning Date
- MMSI 02-25-2025
- PRCT 02-25-2025
- Dividend Yield
- MMSI N/A
- PRCT N/A
- EPS Growth
- MMSI 19.39
- PRCT N/A
- EPS
- MMSI 2.05
- PRCT N/A
- Revenue
- MMSI $1,325,871,000.00
- PRCT $199,843,000.00
- Revenue This Year
- MMSI $9.51
- PRCT $67.07
- Revenue Next Year
- MMSI $8.93
- PRCT $40.64
- P/E Ratio
- MMSI $50.19
- PRCT N/A
- Revenue Growth
- MMSI 8.12
- PRCT 71.71
- 52 Week Low
- MMSI $70.70
- PRCT $44.52
- 52 Week High
- MMSI $108.08
- PRCT $103.81
- Technical
- Relative Strength Index (RSI)
- MMSI 65.31
- PRCT 25.89
- Support Level
- MMSI $100.22
- PRCT $79.56
- Resistance Level
- MMSI $99.34
- PRCT $89.49
- Average True Range (ATR)
- MMSI 1.95
- PRCT 4.14
- MACD
- MMSI 1.00
- PRCT -1.11
- Stochastic Oscillator
- MMSI 94.09
- PRCT 6.09
About MMSI Merit Medical Systems Inc.
Merit Medical Systems Inc is a medical equipment company that develops and manufactures products for use in interventional cardiology, radiology, and endoscopy procedures. The firm reports two segments which are Cardiovascular and Endoscopy. The majority of the revenue is earned from the Cardiovascular segment. The United States generates the majority of the revenue.
About PRCT PROCEPT BioRobotics Corporation
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. It develops, manufactures, and sells the AquaBeam Robotic System,, image-guided, surgical robotic system for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. The company's assets are based in the United States. Its revenue is generated from sales of the AquaBeam Robotic System and the accompanying single-use disposable handpieces.